tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Universal Ibogaine Targets Opioid Treatment Trial

Universal Ibogaine Targets Opioid Treatment Trial

Universal Ibogaine Inc (TSE:IBO) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Universal Ibogaine Inc. is advancing its mission to revolutionize addiction treatment by engaging Changemark Research + Evaluation Ltd. to facilitate a Clinical Trial Application with Health Canada for ibogaine use in opioid addiction. With a 4 to 6 month project timeframe, UI aims to finalize study design for a trial that could significantly impact addiction treatment protocols. The company’s broader vision includes a state-of-the-art holistic addiction treatment protocol at its Kelburn Recovery Centre.

For further insights into TSE:IBO stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1